Catalog No.
Product Name
Application
Product Information
Citations
-
DPP-IV Inhibitor
H-Pro-Pro-Gln-OH is an oligopeptide that acts as a potent inhibitor of dipeptidyl peptidase-IV (DPP-IV). This compound exhibits significant biological activity in modulating insulin secretion and glucose metabolism, making it a valuable tool for diabetes research. Its effective inhibition of DPP-IV may contribute to therapeutic strategies in managing type 2 diabetes and related metabolic disorders. -
DPP-8/9 Inhibitor
DPP-8/9 probe-1 is a selective inhibitor targeting Dipeptidyl Peptidase DPP8/9, designed for use in fluorescence microscopy. This fluorescent probe features a nitrobenzoxadiazole (NBD) tag, demonstrating high affinity for DPP8/9 with an IC50 of 15 nM, while showing minimal activity against related S9 family members (IC50 of 210 nM). DPP-8/9 probe-1 enables visualization of active DPP8/9 in vitro, making it a valuable tool for studying the biological functions and pathways associated with this enzyme in research settings. -
DPP1 Inhibitor
Florensocatib hydrate is a potent inhibitor of dipeptidyl peptidase I (DPP1) with an IC50 value of 1.6 nM. This compound exhibits favorable bioavailability and pharmacokinetic properties, making it suitable for studies investigating inflammatory diseases and related pathophysiological processes. Its ability to modulate DPP1 activity provides a valuable tool for understanding disease mechanisms and exploring potential therapeutic strategies. -
DPP-IV Inhibitor
AMG-222 is a dipeptidyl peptidase IV (DPP-IV) inhibitor that reversibly binds to the enzyme, thereby inhibiting its activity. This compound demonstrates a saturable and concentration-dependent binding to human plasma proteins, achieving a binding rate of 80.8% at 1 nM and decreasing to 29.4% at concentrations above 100 nM. AMG-222 is primarily utilized in diabetes research, aiding studies focused on glucose metabolism and insulin regulation. -
Anti DPP3 Antibody
Invobenitug is a humanized IgG1κ antibody that specifically targets dipeptidyl peptidase 3 (DPP3). This antibody is primarily utilized in research applications focused on understanding the role of DPP3 in various physiological and pathological processes. Its specificity and affinity make it an essential tool for studies related to cellular signaling, metabolism, and disease mechanisms involving DPP3. -
DPP4 Inhibitor
BMS-767778 is a selective DPP4 inhibitor, exhibiting high affinity with Ki values of 0.94 nM for DPP4, and 4.9 nM and 3.2 nM for DPP8 and DPP9, respectively, demonstrating over 3,000-fold selectivity against these related enzymes. This compound also inhibits CYP-3A4 with an IC50 of 5.2 μM. BMS-767778 has been shown to significantly lower blood glucose levels in high-fat diet-induced ob/ob mouse models, indicating its potential for diabetes mellitus research applications. -
DPP-4 Inhibitor
DPP-4-IN-1 is a potent inhibitor of dipeptidyl peptidase 4 (DPP-4) with an IC50 of 49 nM. This compound, structurally analogous to Alogliptin, plays a crucial role in regulating glucose metabolism and enhancing insulin secretion. DPP-4-IN-1 is essential for diabetes research, facilitating investigations into therapeutic strategies for managing hyperglycemia. -
DPP-4 Inhibitor
Denagliptin tosylate is a tosyate salt of Denagliptin, functioning as a potent dipeptidyl peptidase IV (DPP-4) inhibitor. This small molecule effectively enhances incretin levels, contributing to improved glycemic control in type 2 diabetes models. Its applications in research include investigating mechanisms of insulin secretion and glucose metabolism, making it a valuable tool for diabetes-related studies. -
DPP-4 Inhibitor
DPP-4-IN-9 is a potent inhibitor of dipeptidyl peptidase 4 (DPP-4) with an IC50 of 8.22 nM. This compound exhibits significant antihyperglycemic activity, making it a valuable tool for research in diabetes and metabolic disorders. DPP-4-IN-9 is suitable for studies aimed at understanding the role of DPP-4 in glucose metabolism and the development of therapeutic agents targeting this pathway. -
DPP1 Inhibitor
Florensocatib is a potent inhibitor of Dipeptidyl Peptidase I (DPP1), a key enzyme involved in the processing of pro-inflammatory cytokines. This compound exhibits significant biological activity, making it a valuable tool for research in bronchiectasis and related inflammatory diseases. Its selective inhibition of DPP1 provides insights into therapeutic strategies aimed at modulating immune responses. -
DPP-4 Inhibitor
DPP-4-IN-2 is a potent inhibitor of dipeptidyl peptidase 4 (DPP-4) with an IC50 of 79 nM. This compound serves as a structural analog of Alogliptin and is primarily utilized in diabetes research. DPP-4-IN-2 facilitates the investigation of glucose metabolism and insulin signaling pathways, making it a valuable tool for understanding the pathophysiology of type 2 diabetes and developing potential therapeutic strategies. -
DPP1 Inhibitor
DPP-1-IN-1 is a potent inhibitor of Cathepsin C (Dipeptidyl peptidase I) with an IC50 of 5.31 nM. It effectively inhibits the activity of Cathepsin C, subsequently affecting Neutrophil elastase in neutrophils. This compound is valuable for research in the field of inflammatory diseases, providing insights into mechanisms of inflammation and potential therapeutic pathways. -
DPP-4 Inhibitor
TAK-100 is a selective, orally active dipeptidyl peptidase IV (DPP-4) inhibitor, exhibiting an IC50 of 5.3 nM. This compound demonstrates minimal inhibitory effects on other dipeptidyl peptidases, highlighting its specificity. TAK-100 is primarily utilized in research focused on diabetes, facilitating the exploration of glucose metabolism and insulin regulation. -
DPP1 Inhibitor
Propyl-GSK-2793660 is an irreversible and covalent inhibitor of Dipeptidyl Peptidase I (DPP1). This compound exhibits significant biological activity in the modulation of DPP1 activity, making it a valuable tool for studying conditions related to bronchiectasis. Its specificity and mechanism of action can facilitate research on the implications of DPP1 inhibition in various biological contexts. -
DPP-4 Inhibitor
Melogliptin is a DPP-4 inhibitor that plays a crucial role in modulating glucose metabolism. By inhibiting the DPP-4 enzyme, Melogliptin enhances incretin levels, leading to improved insulin secretion and reduced glucagon levels. This compound is primarily utilized in research targeting type 2 diabetes and related metabolic disorders, providing insights into potential therapeutic strategies for glucose regulation. -
DPP-4 Inhibitor
MK-0626 is a selective Dipeptidyl Peptidase-4 (DPP-4) inhibitor, exhibiting an IC50 of 6.3 nM. This compound enhances endothelial nitric oxide synthase expression and is effective in promoting neovascularization. MK-0626 demonstrates potential in mitigating hepatic steatosis and pancreatic islet injury. It is particularly relevant in research focused on diabetes and non-alcoholic fatty liver disease. -
DPP Covalent Inhibitor
Sulphostin is a covalent inhibitor targeting dipeptidyl peptidase 4 (DPP4), dipeptidyl peptidase 9 (DPP9), and dipeptidyl peptidase 8 (DPP8) with IC50 values of 79, 1392, and 6930 nM, respectively. By inducing phosphosulfamate modification, Sulphostin irreversibly inhibits these enzyme activities, making it a valuable tool in the study of inflammatory processes and cancer research. Its selective inhibition profile allows for detailed investigation into the roles of DPPs in various biological pathways. -
DPP4 Inhibitor
P32/98 hemifumarate is a potent dipeptidyl peptidase IV (DPP4) inhibitor with a Ki value of 130 nM. It has been shown to enhance glucose tolerance, improve insulin sensitivity, and increase β-cell responsiveness in a fatty Zucker rat model. This compound is valuable for research applications focused on diabetes and metabolic disorders, providing insights into DPP4 inhibition mechanisms and their effects on glucose homeostasis. -
DPP9 Inhibitor
DPP9-IN-1 is a selective inhibitor of dipeptidyl peptidase 9 (DPP9) with an IC50 value of 3 nM, also exhibiting inhibition of DPP8 at 0.6 μM. This compound has been shown to induce concentration-dependent lactate dehydrogenase (LDH) release in THP-1 cells, indicating potential cytotoxic effects. DPP9-IN-1 is useful in research applications related to immune response modulation and study of DPP9-related pathways in cellular processes. -
DPP4 Inhibitor
P32/98 is a potent dipeptidyl peptidase IV (DPP4) inhibitor, exhibiting a Ki value of 130 nM. This compound is notable for its ability to enhance glucose tolerance, improve insulin sensitivity, and increase β-cell responsiveness, specifically in the fatty Zucker rat model. P32/98 is suitable for research applications targeting metabolic disorders and studying glucose homeostasis. -
DPP4 Inhibitor
SGP8 (IAVPGEVA) is a DPP4 inhibitor that demonstrates significant modulation of lipid metabolism, inflammation, and fibrosis. By inhibiting DPP4 activity, SGP8 affects the JNK-c-Jun signaling pathway and shows potential therapeutic applications in the treatment of non-alcoholic steatohepatitis (NASH). This octapeptide, derived from the hydrolysis of soybean 11S globulin, serves as a valuable tool for research in metabolic disorders and related inflammatory conditions. -
DPP-4 Inhibitor
DPP-4-IN-15 is a non-competitive inhibitor of dipeptidyl peptidase-4 (DPP-4), exhibiting an IC50 value of 8.24 μM. This compound effectively modulates the activity of DPP-4, an enzyme involved in glucose metabolism and insulin regulation. DPP-4-IN-15 is primarily utilized in diabetes research, providing insights into the potential therapeutic effects of DPP-4 inhibition on glycemic control and related metabolic disorders. -
DPP-III Inhibitor
Fluostatin A is a potent inhibitor of dipeptidyl peptidase III (DPP-III), demonstrating an IC50 value of 0.44 μg/mL with the substrate arginyl-arginine-2-naphthalene formamide. By modulating DPP-III activity, Fluostatin A plays a significant role in studies related to peptide metabolism and signaling pathways. This compound is suitable for research applications in diabetes, cardiovascular disease, and other metabolic disorders targeting DPP-III enzymatic regulation. -
DPP-IV inhibitor
AMG-222 tosylate is a potent DPP-IV inhibitor, primarily employed in the investigation of type II diabetes. By modulating the activity of the DPP-IV enzyme, AMG-222 tosylate facilitates enhanced insulin secretion and improved glycemic control. This compound is valuable for research aimed at understanding the mechanisms of glucose homeostasis and developing therapeutic approaches for managing diabetes. -
DPP-3 Inhibitor
Fluostatin B is a dipeptidyl peptidase 3 (DPP-3) inhibitor with an IC50 value of 24 µg/mL. As a natural product derived from Streptomyces, this compound exhibits potential biological activity in modulating peptide metabolism. Fluostatin B is relevant for research applications focused on understanding DPP-3's role in various physiological processes and exploring its implications in disease states such as diabetes and cancer. -
DPP-4 Inhibitor
H-Gly-Pro-Hyp-OH acetate functions as a dipeptidyl peptidase 4 (DPP-4) inhibitor, exhibiting an IC50 value of 2.51 mM. This compound has shown promise in the investigation of diabetes-related pathways and therapeutic strategies. Its ability to modulate DPP-4 activity makes it a valuable reagent for research in metabolic disorders and glucose homeostasis. -
DPP4 Inhibitor
HTS13517 is a selective inhibitor of Dipeptidyl Peptidase IV (DPP4), exhibiting an IC50 value of 10.73 μM. This compound is relevant for studies investigating the modulation of glucose metabolism and the regulation of incretin hormones. Its applications include diabetes research and the exploration of therapeutic strategies targeting metabolic disorders. -
DPP4 Inhibitor
Garvagliptin is a selective and orally active dipeptidyl peptidase-4 (DPP4) inhibitor, achieving an IC50 of 2.99 nM against human recombinant DPP IV. Its primary mechanism facilitates the enhancement of incretin levels, thereby exhibiting antihyperglycemic effects. Garvagliptin is widely utilized in diabetes research to explore its potential in glycemic control and metabolic regulation. -
Aldose Reductase Inhibitor
Zopolrestat is a potent inhibitor of aldose reductase (AR) with an IC50 of 3.1 nM. This compound is primarily utilized in research focused on diabetic complications, providing insights into the metabolic pathways involved in diabetes-related disorders. Its application extends to studying the therapeutic potential in mitigating diabetic neuropathy and retinopathy, making it a valuable tool in diabetes research. -
Aldose Reductase Inhibitor
Ganoderic acid C2 is a bioactive triterpenoid that functions as an aldose reductase inhibitor, displaying an IC50 of 43.8 µM. This compound exhibits potential anti-tumor activity along with antihistamine and anti-aging properties. Its cytotoxic effects make Ganoderic acid C2 a valuable reagent for research in fields such as cancer biology and metabolic disorders. -
Aldose Reductase Inhibitor
6-Hydroxyluteolin is a flavonoid identified as an aldose reductase inhibitor. It demonstrates potential antidiabetic activity by reducing the conversion of glucose to sorbitol, thereby mitigating osmotic and oxidative stress in diabetic tissues. This compound is useful in research applications focused on diabetes-related complications and metabolic disorders. -
Aldose Reductase Inhibitor
Zenarestat is a potent and orally active inhibitor of aldose reductase, an enzyme involved in the polyol pathway. This compound demonstrates significant biological activity by improving symptoms of diabetic peripheral neuropathy in preclinical models, specifically in Zucker diabetic fatty rats. Zenarestat may serve as a valuable tool for research into diabetic complications and the modulation of glucose-related metabolic disorders. -
Aldose Reductase Inhibitor
Exisulind is an aldose reductase inhibitor with an IC50 of 367 nM in vitro. As an inactive metabolite of sulindac, it may play a role in mitigating complications associated with type 2 diabetes through its pharmacological effects. This compound is valuable for research focused on metabolic disorders and the management of diabetes-related complications. -
Aldose Reductase Inhibitor
Lidorestat is a potent and selective aldose reductase inhibitor, exhibiting an IC50 of 5 nM. This compound is primarily used in research focused on chronic complications associated with diabetes. It has demonstrated efficacy in enhancing nerve conduction and reducing the formation of cataracts, making it valuable for studies relating to diabetic neuropathy and cataractogenesis. -
Aldose reductase Inhibitor
Ganoderic acid C6 functions as an aldose reductase inhibitor, effectively modulating glucose metabolism. This compound is important for research aimed at understanding diabetic complications and oxidative stress management. Its potential to influence pathways associated with diabetic neuropathy and retinopathy makes it a valuable reagent for investigating therapeutic strategies in metabolic disorders. -
ACE/NEP Inhibitor
Fasidotril is a dual inhibitor of neprilysin and angiotensin-converting enzyme (ACE). It demonstrates significant biological activity in the modulation of blood pressure and fluid balance, making it a valuable tool in hypertension and congestive heart failure (CHF) research. The compound's ability to inhibit both pathways provides insight into the therapeutic potential for cardiovascular disease management. -
ACE/NEP Inhibitor
AD015 is a dual inhibitor of angiotensin-converting enzyme (ACE) and neprilysin (NEP). It exhibits potent inhibitory activity against NEP, with an IC50 of 0.009 µM, and shows strong inhibition of both nephron ACE (nACE) and cardiac ACE (cACE), with IC50 values of 0.019 µM and 0.0008 µM, respectively. This compound is valuable for research in cardiovascular and renal physiology, particularly in studies related to hypertension and heart failure, where modulation of the renin-angiotensin system is critical. -
NEP Inhibitor
Z-13752A is a mercaptopropanoyl amino acid that functions as an inhibitor of neprilysin (NEP) and angiotensin-converting enzyme (ACE) with Ki values of 1.8 nM and 3.2 nM, respectively. This compound has been shown to effectively reduce arterial blood pressure while enhancing coronary blood flow. Z-13752A is valuable for research focused on coronary artery occlusion and related cardiovascular conditions. -
cACE/NEP Inhibitor
AD011 is a dual inhibitor of carboxypeptidase angiotensin-converting enzyme (cACE) and neprilysin (NEP). This compound is derived from the C-domain selective ACE inhibitor lisinopril-tryptophan and demonstrates significant antihypertensive and cardioprotective effects. AD011 is suitable for research applications focused on cardiovascular health and the modulation of renin-angiotensin system pathways. -
cACE/NEP Inhibitor
AD013 is a dual inhibitor of the enzymes cACE (constitutive Angiotensin-Converting Enzyme) and NEP (Neutral Endopeptidase). This compound is derived from a C-domain selective ACE inhibitor and has demonstrated significant potential in providing antihypertensive and cardioprotective effects. AD013 serves as a valuable reagent for research focused on cardiovascular diseases and hypertension therapies. -
NEP/APN Inhibitor
Sialorphin targets neprilysin (NEP) and aminopeptidase N (APN) as a potent inhibitor, effectively preventing the degradation of key neuropeptides like Substance P and methionine enkephalin. This compound demonstrates significant biological activity, including analgesic effects, modulation of sexual behavior in male rats, and the alleviation of colitis. Additionally, Sialorphin exhibits low toxicity against specific tumor cells, making it a valuable tool for research into pain management, inflammatory bowel disease, and oncology. -
Proteasome Inhibitor
Antitrypanosomal agent 15 is a selective proteasome inhibitor targeting Trypanosoma cruzi, with an impressive pIC50 of 7.4 for the T. cruzi proteasome and minimal activity (pIC50 < 4) against human proteasomes. This orally active compound demonstrates excellent brain penetration and favorable ADME properties, making it suitable for research focused on Chagas disease and related therapeutic interventions. Its selectivity and efficacy highlight its potential for advancing studies in trypanosomiasis. -
PfDHODH Inhibitor
PfDHODH-IN-3 is a potent inhibitor of Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) with an IC50 of 47 nM. This compound exhibits strong antimalarial activity, effectively inhibiting the growth of Plasmodium in animal models. PfDHODH-IN-3 is valuable for research focused on antimalarial drug development and understanding the mechanisms of Plasmodium resistance. -
20S Proteasome Inhibitor
20S Proteasome-IN-4 is a selective inhibitor of the 20S proteasome, exhibiting an IC50 of 6.3 nM against Trypanosoma brucei brucei. This brain-penetrant compound is orally active and demonstrates potential for research into human African trypanosomiasis (HAT). Its specificity for the parasite makes it a valuable tool for studying proteasomal functions in this significant infectious disease. -
Proteasome Inhibitor
LXE408 fumarate is a non-competitive proteasome inhibitor selectively targeting kinetoplastids. It exhibits potent inhibitory activity with an IC50 of 0.04 μM against the L. donovani proteasome, demonstrating an EC50 of 0.04 μM for L. donovani itself. With limited ability to penetrate the blood-brain barrier, LXE408 fumarate is primarily suitable for research in visceral leishmaniasis (VL). -
Proteasome Inhibitor
Carmaphycin-17 is a selective 20S proteasome inhibitor, with an EC50 value of 217 nM. This compound exhibits strong antimicrobial activity against Trichomonas vaginalis, effectively overcoming Metronidazole resistance. It significantly reduces parasite burden in a topical treatment model without noted adverse effects. Carmaphycin-17 is a valuable tool for research on sexually transmitted diseases, specifically trichomoniasis. -
PfDHODH Inhibitor
DSM267 is a triazolopyrimidine compound that preferentially inhibits Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) with an IC50 of 38 nM, demonstrating significant selectivity over human DHODH with an IC50 exceeding 100,000 nM. This reagent is valuable for in vitro systematic screening and characterizing the pathways of resistance evolution in Plasmodium falciparum against DHODH inhibitors. Its use supports research into antimalarial resistance mechanisms and facilitates the development of novel therapeutic strategies. -
Pf Proteasome Inhibitor
Proteasome-IN-8 is a specific inhibitor of the proteasome in Plasmodium falciparum. This compound demonstrates notable antiparasitic activity against the P. falciparum 3D7 strain. It is a valuable tool for research into the mechanisms of malaria pathogenesis and the development of therapeutic strategies targeting parasitic proteasomes. -
DHODH Inhibitor
Genz-669178 is a potent inhibitor of dihydroorotate dehydrogenase (DHODH), demonstrating an IC50 range of 0.015-0.05 μM against Plasmodium species. It effectively inhibits P. berghei and P. falciparum strains 3D7 and Dd2, with respective IC50 values of 0.068, 0.008, and 0.01 μM. In vivo studies indicate that Genz-669178 exhibits significant anti-malarial efficacy in P. berghei-infected mice, with an ED50 of 13-21 mg/kg/day, alongside favorable pharmacokinetic properties. This compound serves as a valuable tool for malaria research and drug development. -
PfDHODH/PbDHODH Inhibitor
DSM74 is a potent inhibitor of dihydroorate dehydrogenase (DHODH) in both Plasmodium falciparum (PfDHODH) and Plasmodium berghei (PbDHODH), with IC50 values of 0.28 μM and 0.38 μM, respectively. This orally active compound exhibits significant antimalarial activity, effectively inhibiting the growth of Plasmodium species in animal models. It is a valuable tool for researchers investigating the mechanisms of malaria and developing novel therapeutic strategies.
